# US 2012/0252806 A1 · Inhibitors of akt activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252806 A1
- Document ID: US20120252806A1
- Status: Published application
- Kind: A1
- Application number: 13/515,326
- Filed: 2010-12-09
- Published: 2012-10-04
- Earliest claimed: 2009-12-17
- Inventors: Michael J. Kelly, III; Mark E. Layton
- Web page: https://patentgrep.com/patent/US20120252806A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

## Claims

### Claim 1

A compound according to the Formula A:
wherein:
a is 0 or 1; b is 0 or 1;
R1 is selected from: H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, aryl, heteroaryl, heterocyclyl, said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or more substituents selected from R2;
R2 is selected from: (C═O)aObC1-C6 alkyl, (C═O)aObC2-C6 alkenyl, (C═O)aObC2-C6 alkynyl, (C═O)aObC3-C8 cycloalkyl, (C═O)aOb aryl, (C═O)aOb heteroaryl, (C═O)aOb-heterocyclyl, OH; oxo, halo, CHO, CO2H, CN, ObC1-C6 perfluoroalkyl and NR3R4, said, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted With one or more substituents selected from R5;
R3 and R4 are independently selected from: H, (C═O)aObC1-C6 alkyl, (C═O)aO2-C6 alkenyl, (C═O)aObC2-C6 alkynyl, (C═O)aObC3-C8 cycloalkyl, (C═O)aOb aryl, (C═O)aObheteroaryl, (C═O)aOb heterocyclyl, OH, oxo, halo, CHO, CO2H, CN, and ObC1-C6 perfluoroalkyl, said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more substituents selected from R5; and
R5 is selected from: C1-C6 alkyl, aryl, heterocyclyl, CO2H, NH2, halo, CN, OH, oxo, and ObC1-C6 perfluoroalkyl, wherein said alkyl, aryl and heterocyclyl is optionally substituted with from one to three substituents selected from OH and NH2;
or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 of the Formula A, wherein:
a is 0 or 1; b is 0 or 1;
R1 is selected from: H, C1-C6 alkyl and heteroaryl, said alkyl and heteroaryl are optionally substituted with one or more substituents selected from R2;
R2 is selected from: (C═O)aObC1-C6 alkyl, (C═O)aOb aryl, (C═O)aOb heteroaryl, (C═O)aOb heterocyclyl, OH, oxo, halo, CHO, CO2H, CN, ObC1-C6 perfluoroalky and NR3R4, said alkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more substituents selected from R5;
R3 and R4 are independently selected from: H, (C═O)aObC1-C6 alkyl, (C═O)aOb aryl, (C═O)aOb heteroaryl, (C═O)aOb heterocyclyl, OH, oxo, halo, CHO, CO2H, CN, and ObC1-C6 perfluoroalkyl, said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more substituents selected from R5; and
R5 is selected from: C1-C6 alkyl, aryl, heterocyclyl, CO2H, NH2, halo, CN, OH, oxo, and ObC1-C6 perfluoroalkyl, wherein said alkyl, aryl and heterocyclyl is optionally substituted with from one to three substituents selected from OH and NH2;
or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 3

A compound which is selected from:
(4-{5-[(benzylamino)carbonyl]-3-phenyl-1,6-naphythyridin-2-yl} phenyl) methanamine;
{4-[5-(aminocarbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
[4-(5{[(isoxazol-3-ylmethyl)amino]carbonyl}-3 -phenyl-1,6-naphthyridin-2-yl)phenyl]methanamine;
{4-[5-({[4-(ammoniomethyl)benzyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
{4-[5-({[1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)ethyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
(4-{3-phenyl-5-[(propylamino)carbonyl]-1,6-naphthridin-2-yl}phenyl)methanamine;
[4-(5-{[(2-hydroxyethyl)amino]carbonyl}-3-phenyl-1,6-naphthyridin-2-yl)phenyl]methanamine;
(4-{5-[(methylamino)carbonyl]-3-phenyl-1,6-naphthyridin-2-yl}phenyl)methanamine;
[4-(3-phenyl-5-{[(1H-pyrazol-5-ylmethyl)amino]carbonyl}-1,6-naphthyridin-2-yl)phenyl]methanamine;
(4-{3-phenyl-5-[(quinoxalin-6-ylamino)carbonyl]-1,6-naphthyridin-2-yl}phenyl)methanamine;
{4[5-({[2-(1H-imidazol-4-yl)ethyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
{4-[5-({[2-(1H-indol-3-yl)ethyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
4-{3-[({2-[4-(ammoniomethyl)phenyl]-3-phenyl-1,6-naphthyridin-5-yl}carbonyl)amino]propyl}morpholine;
[4-(5-{[(2-anilinoethyl)amino]carbonyl}-3-phenyl-1,6-naphthyridin-2-yl)phenyl]methanamine;
{4-[5-({[2-(acetylamino)ethyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
{4-[5-({[3-(1H-imidazol-1-yl)propyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
4-{2-[({2-[4-(ammoniomethyl)phenyl]-3-phenyl-1,6-naphthyridin-5-yl}carbonyl)amino]-1-pyridin-4-ylethyl}morpholine;
4-{2-[({2-[4-(ammoniomethyl)phenyl]-3-phenyl-1,6-naphthyridin-5-yl}carbonyl)amino]-1-pyridin-3-ylethyl}morpholine;
[4-(3-phenyl-5-{[(pyrimidin-2-ylmethyl)amino]carbonyl}-1,6-naphthyridin-2-yl)phenyl]methanamine;
[4-(3-phenyl-5-{[(2-pyrazin-2-ylethyl)amino]carbonyl}-1,6-naphthyridin-2-yl)phenyl]methanamine;
[4-(3-phenyl-5-{[(1H-1,2,3-triazol-4-ylmethyl)amino]carbonyl}-1,6-naphthyridin-2-yl)phenyl]metbanamine;
{4-[3-phenyl-5-({[2-(1,3-thiazol-2-yl)ethyl]amino}carbonyl)-1,6-naphthyridin-2-yl]phenyl}methanamine;
{4-[5-({[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)methyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
1-{2-[({2-[4-(ammoniomethyl)phenyl]-3-phenyl-1,6-naphthyridin-5-yl}carbonyl) amino]ethyl}-4-pyrimidin-2-ylpiperazine;
[4-(5-{[(3H-imidazo[4,5-b]pyridin-2-ylmethyl) amino]carbonyl}-3-phenyl-1,6-naphthyridin-2-yl)phenyl] methanamine;
[4-(5-{[(2-hydroxy-2-pyridin-3-ylethyl)amino]carbonyl}-3-phenyl-1,6-naphthyridin-2-yl)phenyl]methanamine;
{4-[5-({[2-(3,5-dimethylisoxazol-4-yl)ethyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
(4-{5-[({[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methyl}amino)carbonyl]-3-phenyl-1,6-naphthyridin-2-yl}phenyl)methanamine;
[4-(3-phenyl-5-{[(pyridin-2-ylmethyl)amino]carbonyl}-1,6-naphthyridin-2-yl)phenyl]methanamine;
[4-(5-{[(2-oxo-2-phenylethyl)amino]carbonyl}-3-phenyl-1,6-naphthyridin-2-yl)phenyl]methanamine;
[4-(3-phenyl-5-{[(1,3-thiazol-4-ylmethyl)amino]carbonyl}-1,6-naphthyridin-2-yl)phenyl]methanamine;
{4-[5-({[2-(1H-benzimidazol-2-yl)ethyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
{4-[3-phenyl-5-({[2-(1H-pyrazol-4-yl)ethyl]amino}carbonyl)-1,6-naphthyridin-2-yl]phenyl}methanarnine;
{4-[5-({[(methyl-4H-1,2,4-triazol-3-yl)methyl]amino}carbonyl)-3-phenyl-1,6-naphthyridin-2-yl]phenyl}methanamine;
{4-[3-phenyl-5-({[(1-pyrimidin-2-ylpiperidin-3-yl)methyl]amino}carbonyl)-1,6-naphthyridin-2-yl]phenyl}methanamine;
2-{[({2-[4-(aminomethyl)phenyl]-3-phenyl-1,6-naphthyridin-5-yl}carbonyl) amino]methyl}imidazo[1,2-a]pyrimidine;
{4-[3-phenyl-5-({[2-(1H-1,2,4-triazol-5-yl)ethyl] amino}carbonyl)-1,6-naphthyridin-2-yl]phenyl}methanamine; and
{4-[3-phenyl-5-({[(5-phenyl-4H-1,2,4-triazol-3-yl)methyl]amino}carbonyl)-1,6-naphthyridin-2-yl]phenyl}methanamine;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 1.

### Claim 5 (depends on 1)

The use of the compound according to claim 1 for the preparation of a medicament useful in the treatment or prevention of cancer in a mammal in need of such treatment.
